 Connection
Thomas Anchordoquy to Humans
This is a "connection" page, showing publications Thomas Anchordoquy has written about Humans.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.296 |
|
|
|
-
Tilden SG, Ricco MH, Hemann EA, Anchordoquy TJ. Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy. Eur J Pharm Sci. 2025 Jan 01; 204:106974.
Score: 0.022
-
Anchordoquy T, Artzi N, Balyasnikova IV, Barenholz Y, La-Beck NM, Brenner JS, Chan WCW, Decuzzi P, Exner AA, Gabizon A, Godin B, Lai SK, Lammers T, Mitchell MJ, Moghimi SM, Muzykantov VR, Peer D, Nguyen J, Popovtzer R, Ricco M, Serkova NJ, Singh R, Schroeder A, Schwendeman AA, Straehla JP, Teesalu T, Tilden S, Simberg D. Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions. ACS Nano. 2024 06 04; 18(22):13983-13999.
Score: 0.022
-
Tilden SG, Ricco MH, Hemann EA, Anchordoquy TJ. Reducing off-target drug accumulation by exploiting a type-III interferon response. J Control Release. 2023 06; 358:729-738.
Score: 0.020
-
Moghimi SM, Simberg D, Anchordoquy TJ. Tuning the Engines of Nanomedicine. Mol Ther. 2020 03 04; 28(3):693-694.
Score: 0.016
-
Betker JL, Anchordoquy TJ. The Use of Lactose as an Alternative Coating for Nanoparticles. J Pharm Sci. 2020 04; 109(4):1573-1580.
Score: 0.016
-
Anchordoquy TJ, Simberg D. Watching the gorilla and questioning delivery dogma. J Control Release. 2017 09 28; 262:87-90.
Score: 0.013
-
Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia MA, Farhangrazi ZS, Farrell D, Gabizon A, Ghandehari H, Godin B, La-Beck NM, Ljubimova J, Moghimi SM, Pagliaro L, Park JH, Peer D, Ruoslahti E, Serkova NJ, Simberg D. Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. ACS Nano. 2017 01 24; 11(1):12-18.
Score: 0.013
-
Betker JL, Anchordoquy TJ. Effect of charge ratio on lipoplex-mediated gene delivery and liver toxicity. Ther Deliv. 2015; 6(11):1243-53.
Score: 0.012
-
Betker JL, Anchordoquy TJ. Relating toxicity to transfection: using sphingosine to maintain prolonged expression in vitro. Mol Pharm. 2015 Jan 05; 12(1):264-73.
Score: 0.011
-
Kullberg M, McCarthy R, Anchordoquy TJ. Gene delivery to Her-2+ breast cancer cells using a two-component delivery system to achieve specificity. Nanomedicine. 2014 Aug; 10(6):1253-62.
Score: 0.011
-
Kullberg M, McCarthy R, Anchordoquy TJ. Systemic tumor-specific gene delivery. J Control Release. 2013 Dec 28; 172(3):730-6.
Score: 0.010
-
Betker JL, Gomez J, Anchordoquy TJ. The effects of lipoplex formulation variables on the protein corona and comparisons with in vitro transfection efficiency. J Control Release. 2013 Nov 10; 171(3):261-8.
Score: 0.010
-
Betker JL, Kullberg M, Gomez J, Anchordoquy TJ. Cholesterol domains enhance transfection. Ther Deliv. 2013 Apr; 4(4):453-62.
Score: 0.010
-
Kullberg M, Mann K, Anchordoquy TJ. Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO. Mol Pharm. 2012 Jul 02; 9(7):2000-8.
Score: 0.009
-
Xu L, Betker J, Yin H, Anchordoquy TJ. Ligands located within a cholesterol domain enhance gene delivery to the target tissue. J Control Release. 2012 May 30; 160(1):57-63.
Score: 0.009
-
Xu L, Wempe MF, Anchordoquy TJ. The effect of cholesterol domains on PEGylated liposomal gene delivery in vitro. Ther Deliv. 2011 Apr; 2(4):451-60.
Score: 0.009
-
Xu L, Anchordoquy T. Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci. 2011 Jan; 100(1):38-52.
Score: 0.009
-
Xu L, Anchordoquy TJ. Effect of cholesterol nanodomains on the targeting of lipid-based gene delivery in cultured cells. Mol Pharm. 2010 Aug 02; 7(4):1311-7.
Score: 0.008
-
Xu L, Anchordoquy TJ. Cholesterol domains in cationic lipid/DNA complexes improve transfection. Biochim Biophys Acta. 2008 Oct; 1778(10):2177-81.
Score: 0.007
-
Molina MD, Anchordoquy TJ. Degradation of lyophilized lipid/DNA complexes during storage: the role of lipid and reactive oxygen species. Biochim Biophys Acta. 2008 Oct; 1778(10):2119-26.
Score: 0.007
-
Zhang Y, Bradshaw-Pierce EL, Delille A, Gustafson DL, Anchordoquy TJ. In vivo comparative study of lipid/DNA complexes with different in vitro serum stability: effects on biodistribution and tumor accumulation. J Pharm Sci. 2008 Jan; 97(1):237-50.
Score: 0.007
-
Barnes A, Gaikwad HK, Siegel D, Angarita D, Nebbia M, Anchordoquy T, Bourne D, Stewart M, Yildirim A, Fierro Cota MM, Duffy JT, Haupt BE, Balyasnikova IV, Simberg D. Role of Serum Stability and Lipoprotein Interactions in Lipid Structure-Tumor Accumulation Relationship. ACS Nano. 2025 Oct 21; 19(41):36435-36450.
Score: 0.006
-
Lengsfeld CS, Anchordoquy TJ. Shear-induced degradation of plasmid DNA. J Pharm Sci. 2002 Jul; 91(7):1581-9.
Score: 0.005
-
Fogueri U, Charkoftaki G, Roda G, Tuey S, Ibrahim M, Persaud I, Wempe MF, Brown JM, Thurman JM, Anchordoquy TJ, Joy MS. An evaluation of a novel nanoformulation of imatinib mesylate in a mouse model of lupus nephritis. Drug Deliv Transl Res. 2022 06; 12(6):1445-1454.
Score: 0.004
-
Crommelin DJA, Anchordoquy TJ, Volkin DB, Jiskoot W, Mastrobattista E. Addressing the Cold Reality of mRNA Vaccine Stability. J Pharm Sci. 2021 03; 110(3):997-1001.
Score: 0.004
-
Anchordoquy TJ, Koe GS. Physical stability of nonviral plasmid-based therapeutics. J Pharm Sci. 2000 Mar; 89(3):289-96.
Score: 0.004
-
Oushy S, Hellwinkel JE, Wang M, Nguyen GJ, Gunaydin D, Harland TA, Anchordoquy TJ, Graner MW. Glioblastoma multiforme-derived extracellular vesicles drive normal astrocytes towards a tumour-enhancing phenotype. Philos Trans R Soc Lond B Biol Sci. 2018 Jan 05; 373(1737).
Score: 0.003
-
Redzic JS, Gomez JD, Hellwinkel JE, Anchordoquy TJ, Graner MW. Proteomic analyses of brain tumor cell lines amidst the unfolded protein response. Oncotarget. 2016 Jul 26; 7(30):47831-47847.
Score: 0.003
-
Hellwinkel JE, Redzic JS, Harland TA, Gunaydin D, Anchordoquy TJ, Graner MW. Glioma-derived extracellular vesicles selectively suppress immune responses. Neuro Oncol. 2016 Apr; 18(4):497-506.
Score: 0.003
-
Pozzi D, Caracciolo G, Capriotti AL, Cavaliere C, La Barbera G, Anchordoquy TJ, Laganà A. Surface chemistry and serum type both determine the nanoparticle-protein corona. J Proteomics. 2015 Apr 24; 119:209-17.
Score: 0.003
-
Verhoef JJ, Carpenter JF, Anchordoquy TJ, Schellekens H. Potential induction of anti-PEG antibodies and complement activation toward PEGylated therapeutics. Drug Discov Today. 2014 Dec; 19(12):1945-52.
Score: 0.003
-
Epple LM, Griffiths SG, Dechkovskaia AM, Dusto NL, White J, Ouellette RJ, Anchordoquy TJ, Bemis LT, Graner MW. Medulloblastoma exosome proteomics yield functional roles for extracellular vesicles. PLoS One. 2012; 7(7):e42064.
Score: 0.002
-
Abrams DJ, Zheng L, Choo KS, Yang JJ, Wei W, Anchordoquy TJ, Zawia NH, Stevens KE. An initial animal proof-of-concept study for central administration of clozapine to schizophrenia patients. Schizophr Res. 2008 Mar; 100(1-3):86-96.
Score: 0.002
-
Lentz YK, Anchordoquy TJ, Lengsfeld CS. Rationale for the selection of an aerosol delivery system for gene delivery. J Aerosol Med. 2006; 19(3):372-84.
Score: 0.002
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|